Psyence Biomedical Ltd. Stock Price, News & Analysis

Psyence BioMed (Nasdaq: PBM) announced that its strategic partner, PsyLabs, has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract meeting food-grade consumption safety standards. This achievement follows PBM's strategic equity investments in PsyLabs during 2024 and 2025.

The breakthrough represents a significant milestone in producing high-quality psychedelic APIs, with PsyLabs' extract passing third-party laboratory verification. The company is expanding its chemistry production facilities to meet growing demand for Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs derived from Iboga and Mushrooms.

The products will be available to licensed research institutions and developers globally, ensuring reliable and ethical sourcing of psychedelic compounds.

Psyence BioMed (NASDAQ: PBM) announced that Mary-Elizabeth Gifford, Chief of Global Impact, will be a featured speaker at Psychedelic Science 2025 (PS2025) in Denver from June 16-20, 2025. The conference, hosted by MAPS, is the world's largest gathering focused on psychedelic research and industry developments. Gifford will join notable industry leaders including Jody Aufrichtig (Psyence BioMed), Tony Budden (PsyLabs), and executives from COMPASS Pathways, Cybin Inc., and other prominent organizations. The Business Track will address commercial aspects of the psychedelic industry, with billions in investments flowing into research and drug development. Gifford will present on business ethics in a panel titled "We are the Guardrails: Profit with Purpose," representing Psyence BioMed's commitment to ethical practices in psychedelic medicine development.

Psyence Biomedical Ltd. (NASDAQ: PBM) has successfully regained full compliance with Nasdaq's continued listing requirements, following a compliance hearing on May 29, 2025. The company implemented a 1-for-7.97 reverse stock split, approved by shareholders on April 16, 2025, to meet Nasdaq's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). CEO Dr. Neil Maresky highlighted the company's strong financial position, including a debt-free balance sheet and robust cash reserves. Psyence BioMed focuses on developing nature-derived therapeutics, specifically using psilocybin and Ibogaine, targeting unmet needs in palliative care, addiction, and mental health conditions.

Psyence BioMed (NASDAQ: PBM) has finalized a service agreement with Southern Star Research, an award-winning Australian CRO, to manage their Phase IIb clinical trial investigating psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients. The double-blind, placebo-controlled study will enroll 87 participants to assess three doses of psilocybin combined with psychotherapy.

Southern Star Research, recipient of the 2024 Asia-Pacific Competitive Strategy Leadership Award, brings 14 years of expertise in oncology and mental health trials. They will oversee full trial management, including clinical monitoring, project management, and data handling. The study addresses a significant unmet need, as Adjustment Disorder affects up to 19% of cancer patients.

Additionally, FDA Commissioner Marty Makary has expressed support for psychedelic medicine, promising an "expeditious and rapid review" of clinical data from psychedelic trials under the Trump administration.

Psyence BioMed (NASDAQ: PBM) has announced a 1-for-7.97 reverse stock split effective May 5, 2025. The consolidation, approved by shareholders on April 16, aims to regain compliance with Nasdaq's minimum bid price requirement. Following the split, PBM's outstanding shares will decrease from 4,648,610 to 583,263. The stock will continue trading under the symbol "PBM" with a new CUSIP number 74449F308. No fractional shares will be issued - fractions less than 0.5 will be rounded down, while those 0.5 or greater will be rounded up. The consolidation affects all shareholders uniformly and won't alter percentage interests except for minor adjustments from fractional shares. Continental Stock Transfer & Trust Company serves as the exchange agent.

Psyence BioMed (NASDAQ: PBM) has received a notification from Nasdaq on April 16, 2025, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company's stock price remained below this threshold for 30 consecutive business days from March 5 through April 15, 2025.

Following a previous monitoring period granted on December 20, 2024, this notification constitutes a Staff Delisting Determination. PBM plans to appeal and request a hearing, which will temporarily stay the suspension of trading and delisting.

To address this issue, shareholders approved a reverse stock split at a Special Meeting on April 16, 2025, with the Board of Directors setting a final ratio of 1-for-7.97. While trading continues under 'PBM', there is no guarantee the company will successfully appeal or regain compliance with Nasdaq listing requirements.

Psyence BioMed (NASDAQ: PBM) has announced a USD $500,000 follow-on investment in PsyLabs, strengthening their partnership in psychedelic medicine development. This builds upon their September 2024 agreement where PBM acquired an 11.13% equity stake in PsyLabs.

The investment includes two key components:

• An exclusive, royalty-bearing IP licensing agreement for pharmaceutical-grade, EU-GMP, nature-derived psilocybin supply
• An exclusive right of first refusal for worldwide supply of pharmaceutical-grade, nature-derived Ibogaine

The partnership focuses on developing treatments for Substance Use Disorders (SUD), including Alcohol Use Disorder (AUD). PsyLabs will provide Psyence BioMed with high-quality psychedelic compounds to support their clinical pipeline and therapeutic development efforts. The deal is subject to definitive agreements and regulatory approvals.

Psyence BioMed (NASDAQ: PBM) has signed a Letter of Intent with Southern Star Research, an Australian contract research organization, to expand its Phase IIb clinical trial for psilocybin-assisted therapy. The trial focuses on treating adjustment disorder in cancer patients.

The partnership aims to accelerate the clinical trial timeline by leveraging Southern Star Research's national oncology and mental health network. Adjustment disorder, the seventh most frequently diagnosed psychiatric condition globally, currently lacks FDA-approved pharmaceutical treatments.

The company is transitioning trial management responsibilities from iNGENū CRO to Southern Star Research to ensure operational efficiency. A corporate webinar discussing the new agreement is scheduled for April 10, 2025, at 12:00 PM EST.

Psyence Biomedical (NASDAQ: PBM) provided a corporate update highlighting its progress in psychedelic medicine development. The company is conducting a Phase IIb clinical trial in Australia, focusing on adjustment disorder in cancer patients, benefiting from up to 43.5% R&D tax rebates and favorable regulatory framework.

The company has secured an exclusive IP licensing agreement with PsyLabs for EU-GMP certified psychedelic compounds, including psilocin, mescaline, ibogaine, and DMT. They've strengthened their Scientific Advisory Board with Dr. Dan Stein and Dr. Al Garcia-Romeu from Johns Hopkins.

PBM is planning a new clinical trial for Alcohol Use Disorder (AUD) and Substance Use Disorders. The company maintains a debt-free status with access to ATM financing and Equity Line of Credit (ELOC) for capital needs. A corporate webinar is scheduled for April 10, 2025, to discuss ongoing initiatives and future plans.